Rachel is a member of Pfizer’s Access & Value team. She joined in 2018 as the HTA Team leader supporting the submission of reimbursement dossiers to NICE, SMC & AWMSG but has gone on to lead projects looking at policy and methods changes required to enable health inequalities and the wider social determinants of health to be included in reimbursement discussions.
Prior to this Rachel spent 2 years as the Director of Business Operations for Medical Affairs (in International Developed Markets), and 2 years with the Pfizer Internal Consulting Group utilising continuous improvement methodologies and operational consulting skills to support business process re-engineering, transformation and continuous improvement initiatives on behalf of Pfizer’s Global and Regional commercial organisation. In 2011 Rachel spent a year drafting business plan for a successful €70M European grant application for a Stem Cell start-up company on behalf of Pfizer. And before this worked within Pfizer’s Research unit in Sandwich leading a variety of pre-clinical projects in the Sexual Health, Pain and Inflammation therapeutic areas, managing the exploratory plate-based assay development team and culminating in her becoming head of the Primary Plate Based Pharmacology Department. Rachel started her career at Wellcome in the atherosclerosis field before going onto to study for a PhD at Nottingham University looking at the role of nitric oxide in regional haemodynamics in diabetes and then joining Pfizer. Rachel completed an MBA part time at Ashridge Business school whilst working in the Pfizer Consulting team.
